Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).

被引：0
|
作者：
Aapro, Matti S.
Rossi, Giorgia
Rizzi, Giada
Palmas, Marco
Grunberg, Steven
机构：
[1] Clin Genolier, Genolier, Switzerland
[2] Helsinn Healthcare SA, Lugano, Switzerland
[3] Fletcher Allen Hlth Care, Burlington, VT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9514
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
    Lorusso, Vito
    Russo, Anna
    Giotta, Francesco
    Codega, Paolo
    CORE EVIDENCE, 2020, 15 : 21 - 29
  • [32] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC)
    Hesketh, Paul Joseph
    Schwartzberg, Lee Steven
    Modiano, Manuel R.
    Arora, Sujata
    Poma, Allen
    Schnadig, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
    Boccia, Ralph V.
    Cooper, William
    O'Boyle, Erin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Moderately Emetogenic (MEC) Chemotherapy in Patients with Breast Cancer
    Webb, T.
    Hardwick, J.
    Carides, A. D.
    Street, J. C.
    CANCER RESEARCH, 2009, 69 (24) : 575S - 576S
  • [35] SAFETY AND EFFICACY OF ORAL PALONOSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
    Voisin, D.
    Grunberg, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 507 - 507
  • [36] Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)
    Zelek, L.
    Debourdeau, P.
    Bourgeois, H.
    Wagner, J. P.
    Brocard, F.
    Lefeuvre-Plesse, C.
    Chauffert, B.
    Leheurteur, M.
    Bachet, J-B.
    Simon, H.
    Mayeur, D.
    Jovenin, N.
    Scotte, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1175 - S1175
  • [37] Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
    Simhadri, Soumya
    Dayyala, Sowmya
    Musinipally, Anjani Devi
    Guram, Lavanya
    Madavi, Mamatha
    Kancha, Ramakrishna
    Puligundla, Krishna Chaitanya
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [38] The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
    Vaswani, Bharat
    Dattatreya, Palanki S.
    Barkate, Hanmant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Jadhav, Amit Y.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [39] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [40] Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Zelek, Laurent
    Navari, Rudolph
    Aapro, Matti
    Scotte, Florian
    CANCER MEDICINE, 2023, 12 (15): : 15769 - 15776
12345